<unk>  is a monoclonal antibody that is FDA approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture, increase bone mass in men with osteoporosis, bone loss in men receiving androgen deprivation therapy for prostate cancer, bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer.   Common adverse reactions include hypercholesterolemia, diarrhea, nausea, vomiting, arthralgia, backache, pain in limb, asthenia, headache, cystitis, nasopharyngitis, upper respiratory infection, fatigue.
Denosumab
Zoledronic acid
Alendronate
Risedronate
Teriparatide
Tiludronate
Zoledronate
Etidronate